Literature DB >> 22504891

Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial?

Rob Mac Sweeney, Daniel Francis McAuley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504891     DOI: 10.1136/thoraxjnl-2011-201309

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  5 in total

Review 1.  MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy.

Authors:  Konstantinos Sdrimas; Stella Kourembanas
Journal:  Antioxid Redox Signal       Date:  2014-02-24       Impact factor: 8.401

Review 2.  Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies.

Authors:  Carsten W Lederer; Lola Koniali; Tina Buerki-Thurnherr; Panayiota L Papasavva; Stefania La Grutta; Amelia Licari; Frantisek Staud; Donato Bonifazi; Marina Kleanthous
Journal:  Pharmaceutics       Date:  2022-04-05       Impact factor: 6.525

Review 3.  Current Pharmacological Approach to ARDS: The Place of Bosentan.

Authors:  Omer Araz
Journal:  Eurasian J Med       Date:  2020-02

4.  Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome.

Authors:  Youjin Chang; So Hee Park; Jin-Won Huh; Chae-Man Lim; Younsuck Koh; Sang-Bum Hong
Journal:  J Korean Med Sci       Date:  2014-02-27       Impact factor: 2.153

5.  Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p.

Authors:  Mingyang Shao; Qing Xu; Zhenru Wu; Yuwei Chen; Yuke Shu; Xiaoyue Cao; Menglin Chen; Bo Zhang; Yongjie Zhou; Rong Yao; Yujun Shi; Hong Bu
Journal:  Stem Cell Res Ther       Date:  2020-01-23       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.